Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, Chinese Systemic Lupus Erythematosus Treatment and Research Group, et al. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus[J]. Chinese Rheumatology Association; National Clinical Research Center for Dermatologic and Immunologic Diseases; Chinese Systemic Lupus Erythematosus Treatment and Research Group, 2020, 59(3): 172-185. doi: 10.3760/cma.j.issn.0578-1426.2020.03.002

CASSIA M, ALBERICI F, GALLIENI M, et al. Lupus nephritis and B-cell targeting therapy[J]. Expert Rev Clin Immunol, 2017, 13(10): 951-962. doi: 10.1080/1744666X.2017.1366855

ZHANG F C, BAE S C, BASS D, et al. A pivotal phase Ⅲ, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J]. Ann Rheum Dis, 2018, 77(3): 355-363. doi: 10.1136/annrheumdis-2017-211631

Chinese Lupus nephritis Diagnosis and Treatment Guideline Compilation Group. Chinese Guidelines for the diagnosis and treatment of lupus nephritis[J]. National Medical Journal of China, 2019, 99(44): 3441-3455. doi: 10.3760/cma.j.issn.0376-2491.2019.44.001

XIE C H, LI Z J. Diagnosis and treatment of systemic lupus erythematosus[J]. Chinese general practice, 2020, 18(4): 527-528. http://www.zhqkyx.net/article/id/240c4592-9f47-4c70-a324-2bf8221505c8

ANDERS H J, SAXENA R, ZHAO M H, et al. Lupus nephritis[J]. Nat Rev Dis Primers, 2020, 6(1): 7. doi: 10.1038/s41572-019-0141-9

KRONBICHLER A, BREZINA B, GAUCKLER P, et al. Refractory lupus nephritis: When, why and how to treat[J]. Autoimmun Rev, 2019, 18(5): 510-518. doi: 10.1016/j.autrev.2019.03.004

MURPHY G, ISENBERG D A. New therapies for systemic lupus erythematosus: Past imperfect, future tense[J]. Nat Rev Rheumatol, 2019, 15(7): 403-412. doi: 10.1038/s41584-019-0235-5

SAMY E, WAX S, HUARD B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases[J]. Int Rev Immunol, 2017, 36(1): 3-19. doi: 10.1080/08830185.2016.1276903

BLAIR H A, DUGGAN S T. Belimumab: A review in systemic lupus erythematosus[J]. Drugs, 2018, 78(3): 355-366. doi: 10.1007/s40265-018-0872-z

FANOURIAKIS A, KOSTOPOULOU M, ALUNNO A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736-745. doi: 10.1136/annrheumdis-2019-215089

ADAMICHOU C, GEORGAKIS S, BERTSIAS G. Cytokine targets in lupus nephritis: Current and future prospects[J]. Clin Immunol, 2019, 206: 42-52. doi: 10.1016/j.clim.2018.08.013

FURIE R, ROVIN BN, HOUSSIAU F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117-1128. doi: 10.1056/NEJMoa2001180

BINDA V, TREZZI B, DEL P N, et al. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient)[J]. J Nephrol, 2020, 33(5): 1019-1025. doi: 10.1007/s40620-020-00706-3

MARGIOTTA D P E, BASTA F, BATANI V, et al. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class Ⅳ lupus nephritis: Case series and literature review[J]. BMC Nephrol, 2018, 19(1): 54. doi: 10.1186/s12882-018-0847-z

SCIASCIA S, RADIN M, YAZDANY J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review[J]. Autoimmun Rev, 2017, 16(3): 287-293. doi: 10.1016/j.autrev.2017.01.010

FLIEBER E E, KORSTEN P, KOZIOLEK M J, et al. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman[J]. Lupus, 2013, 22(14): 1523-1525. doi: 10.1177/0961203313504145